Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Cytokinetics, Incorporated before investing.

In this article, we go over a few key elements for understanding Cytokinetics, Incorporated’s stock price such as:

• Cytokinetics, Incorporated’s current stock price and volume
• Why Cytokinetics, Incorporated’s stock price changed recently
• Upgrades and downgrades for CYTK from analysts
• CYTK’s stock price momentum as measured by its relative strength

About Cytokinetics, Incorporated (CYTK)

Before we jump into Cytokinetics, Incorporated’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Want to learn more about Cytokinetics, Incorporated’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Cytokinetics, Incorporated.

Cytokinetics, Incorporated’s Stock Price as of Market Close

As of May 06, 2026, 11:32 AM, CST, Cytokinetics, Incorporated’s stock price was $74.040.

Cytokinetics, Incorporated is down 3.96% from its previous closing price of $77.090.

During the last market session, Cytokinetics, Incorporated’s stock traded between $73.020 and $79.010. Currently, there are approximately 120.10 million shares outstanding for Cytokinetics, Incorporated.

Cytokinetics, Incorporated’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Cytokinetics, Incorporated Stock Price History

Cytokinetics, Incorporated’s (CYTK) price is currently up 15.74% so far this month.

During the month of May, Cytokinetics, Incorporated’s stock price has reached a high of $80.200 and a low of $62.920.

Over the last year, Cytokinetics, Incorporated has hit prices as high as $80.200 and as low as $29.310. Year to date, Cytokinetics, Incorporated’s stock is up 16.53%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Cytokinetics, Incorporated Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 05, 2026, there was 1 analyst who downgraded Cytokinetics, Incorporated’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Cytokinetics, Incorporated’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Cytokinetics, Incorporated’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Cytokinetics, Incorporated (CYTK) by visiting AAII Stock Evaluator.

Relative Price Strength of Cytokinetics, Incorporated

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 05, 2026, Cytokinetics, Incorporated has a weighted four-quarter relative price strength of 15.32%, which translates to a Momentum Score of 86 and is considered to be Very Strong.

Want to learn more about how Cytokinetics, Incorporated is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Cytokinetics, Incorporated Stock Price: Bottom Line

As of May 6, 2026, Cytokinetics, Incorporated’s stock price is $74.040, which is down 3.96% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Cytokinetics, Incorporated stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.